No more invasive or painful methods!
Detection of prostate cancer.
New diagnostic technology
The main advantage of measuring this molecular marker is that the result of this analysis is not affected by non-cancerous prostatic diseases such as Benign Prostatic Hyperplasia (BPH) or Prostatitis.
With a simple urine sample, prostate cancer can be identified early.
This test offers up to 92% certainty in the diagnosis for prostate cancer.
This is due to the fact that PSA is a protein normally produced by prostate cells which, when seen, increases its value in blood serum, it is only an indicator of prostatic tissue inflammation, which does not mean cancer.
(2009) Daphne Hessels & Jack A. Schalken. The use of PCA3 in the diagnosis of prostate cancer. Nature Reviews Urology volume6, pages 255–261
(2018) Kamil Szeliskiet al. Modern urology perspectives on prostate cancer biomarkers
(2010) Dorian V Saavedra-Briones et al. Initial experience in prostate cancer detection in Mexican patients at the Hospital General Dr. Manuel Gea González using a low-cost PCA3 test. Revista Mexicana de Urología.
(2018) Jiang Z et al. Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies: a meta-analysis. Minerva Urol Nefrol